PE20080985A1 - Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano - Google Patents

Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano

Info

Publication number
PE20080985A1
PE20080985A1 PE2007001164A PE2007001164A PE20080985A1 PE 20080985 A1 PE20080985 A1 PE 20080985A1 PE 2007001164 A PE2007001164 A PE 2007001164A PE 2007001164 A PE2007001164 A PE 2007001164A PE 20080985 A1 PE20080985 A1 PE 20080985A1
Authority
PE
Peru
Prior art keywords
biciclo
azonia
isoxazol
carbamoyl
octane
Prior art date
Application number
PE2007001164A
Other languages
English (en)
Inventor
Stephanie Monnier
Gerhard Muhrer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20080985A1 publication Critical patent/PE20080985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN CRISTAL POLIMORFICO DE BROMURO DE (R)-3-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-(ISOXAZOL-3-IL-CARBAMOIL-METIL)-1-AZONIA-BICICLO-[2.2.2]-OCTANO, DESIGNADO COMO LA FORMA DEL CRISTAL T ALFA, CARACTERIZADA POR UN PUNTO DE FUSION 208ºC, CON LAS LINEAS DE DIFRACION (2 THETA EN GRADOS ANGULARES ± 0.2ºC) EN EL PATRON DE DIFRACCION DE RAYOS X DE: 5.7º, 15.7º, 18.5º, 19.8º, 21.1º, 22.2º Y 24.0º. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA PARA ADMINISTRACION TOPICA O EN AEROSOL CON UN DIAMETRO DE PARTICULA DE HASTA 10 MICRAS, OPCIONALMENTE JUNTO CON SUSTANCIAS ANTIINFLAMATORIAS, BRONCODILATADORAS, ANTIALERGICAS Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR MUSCARINICO M3 UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS U OBSTRUCTIVAS DE LAS VIAS RESPIRATORIAS
PE2007001164A 2006-08-31 2007-08-28 Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano PE20080985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119883A EP1900737A1 (en) 2006-08-31 2006-08-31 Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Publications (1)

Publication Number Publication Date
PE20080985A1 true PE20080985A1 (es) 2008-09-05

Family

ID=37685707

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001164A PE20080985A1 (es) 2006-08-31 2007-08-28 Forma polimorfica de cristal talfa de bromuro de (r)-3-(2-hidroxi-2,2-difenil-acetoxi)-1-(isoxazol-3-il-carbamoil-metil)-1-azonia-biciclo-[2.2.2]-octano

Country Status (21)

Country Link
US (1) US20090264461A1 (es)
EP (2) EP1900737A1 (es)
JP (1) JP2010501611A (es)
KR (1) KR20090051110A (es)
CN (1) CN101506205A (es)
AR (1) AR062582A1 (es)
AU (1) AU2007291515A1 (es)
BR (1) BRPI0716205A2 (es)
CA (1) CA2660983A1 (es)
CL (1) CL2007002524A1 (es)
GT (1) GT200900044A (es)
IL (1) IL196808A0 (es)
MA (1) MA31412B1 (es)
MX (1) MX2009002300A (es)
NO (1) NO20091231L (es)
PE (1) PE20080985A1 (es)
RU (1) RU2009111390A (es)
TN (1) TN2009000069A1 (es)
TW (1) TW200817399A (es)
WO (1) WO2008025541A1 (es)
ZA (1) ZA200900449B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
ES2425581T3 (es) * 2006-11-23 2013-10-16 Sinoxa Pharma Gmbh Composiciones farmacéuticas para el tratamiento de la arteriopatía capilar

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.

Also Published As

Publication number Publication date
TN2009000069A1 (en) 2010-08-19
KR20090051110A (ko) 2009-05-20
NO20091231L (no) 2009-03-25
BRPI0716205A2 (pt) 2013-11-12
IL196808A0 (en) 2009-11-18
EP2064210A1 (en) 2009-06-03
ZA200900449B (en) 2010-01-27
JP2010501611A (ja) 2010-01-21
MX2009002300A (es) 2009-03-20
GT200900044A (es) 2012-01-16
AU2007291515A1 (en) 2008-03-06
MA31412B1 (fr) 2010-06-01
RU2009111390A (ru) 2010-10-10
AR062582A1 (es) 2008-11-19
CN101506205A (zh) 2009-08-12
US20090264461A1 (en) 2009-10-22
EP1900737A1 (en) 2008-03-19
WO2008025541A1 (en) 2008-03-06
CA2660983A1 (en) 2008-03-06
TW200817399A (en) 2008-04-16
CL2007002524A1 (es) 2008-07-11

Similar Documents

Publication Publication Date Title
ES2280538T3 (es) Nuevo ligando para receptores nicotinicos de acetilcolina utiles en terapia.
ECSP077424A (es) Derivados de quinuclidina y su uso como antagonistas del receptor muscarínico m3
JP2009541443A5 (es)
IL171591A (en) Quinuclidine derivatives, process for their preparation and use thereof for the manufacture of medicaments for the treatment of conditions mediated by the muscarinic m3 receptor
JP2008519794A5 (es)
CO6270364A2 (es) Derivados de piridina y pirazina utiles en el tratamiento de trastornos de proliferacion celular
KR20170042595A (ko) 의약으로서의 rip1 키나제 억제제로서의 헤테로시클릭 아미드
CN104520291A (zh) 用于调节egfr活性的化合物和组合物
JP2013542247A5 (es)
TW200724541A (en) Imidazoquinolines as lipid kinase inhibitors
UY29245A1 (es) Combinaciones medicas
TN2015000505A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CL2008001345A1 (es) Compuestos derivados de imidazo[1,2-b]piridazinas, inhibidores de cinasa; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su proceso de preparacion; y su uso en enfermedades hiperproliferativas, inflamatorias, alergicas y obstructivas de las vias respiratorias, entre otras.
IL193951A (en) A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound.
UY29244A1 (es) Combinaciones medicas
TW200813045A (en) Fused bicycloheterocycle substituted azabicyclic alkane derivatives
CL2009000120A1 (es) Compuestos derivados de carboxamidas n-aza-biciclicas; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso como antagonistas o agonistas del receptor tipo trpv1 para tratar el dolor, la inflamacion, trastornos metabolicos, urologicos, ginecologicos, gastrointestinales, respiratorios.
AR075104A1 (es) Compuesto de piperazin-aril-purina, su uso para preparar un medicamento util para el tratamiento del dolor y composicion farmaceutica que lo comprende
PE20150671A1 (es) Antagonistas del receptor de 5-ht3
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
IL204064A (en) Compounds 4-Formylphiprazine-1-Carboxamidine Efficacy as Muscarinic Receptor Antagonists
AR062471A1 (es) SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU
AR066701A1 (es) 3-( imidazolil)- pirazolo {3,4-b] piridinas, composicion farmaceutica, proceso y uso en terapia
GB2468073A (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
HRP20120918T1 (hr) Aminopirazolski spoj

Legal Events

Date Code Title Description
FC Refusal